Prostat kanserlerinin tedavisinde HİFU’nun yeri HIFU (Yüksek Yoğunluklu Odaklanmış Ultrason)

Year 2017, Volume: 12 Issue: 3, 72 - 83, 01.10.2017

Bilal Günaydın Turhan Çaşkurlu

Abstract

Güncel tedavi kılavuzlarında prostat kanserli hastalarda, radikal prostatektomi ve radyoterapi önerilen standart tedavi modaliteleridir. 1980’li yıllarda piezoelektrik kaynakların dokularda meydana getirdiği biyolojik etkilerin anlaşılmasıyla birlikte prostat kanserinde yeni bir tedavi modalitesi olarak yüksek yoğunluklu odaklanmış ultrason (HIFU) tedavisi kullanıma girmiştir. HIFU tedavisi, klinik kullanıma girdiği ilk yıllarda yaş ve komorbiditelerinden dolayı cerrahi için uygun olmayan hastalarda kullanılmıştır. Ancak teknolojik gelişmeler ve klinik tecrübelerin artmasıyla günümüzde prostat kanserlerinin primer, kurtarma ve fokal tedavilerinde tercih edilmektedir. Avrupa ülkelerinde lokal hastalığın tedavisinde önerilmesine rağmen (Avrupa üroloji kılavuzunda lokalize düşük dereceli prostat kanserinde öneri derecesi 3, kanıt derecesi C), ABD’de prostat ablasyonu için FDA onayını 2015 yılında alabilmiştir. 

Bu derlemede prostat kanserinde HIFU yönteminin çalışma prensibi, güncel cihazları, tedavi endikasyonları, etkinliği ve sonuçları tartışılmıştır. 

Keywords

Prostat kanseri , HIFU , Fokal Tedavi

High intensity focused ultrasound (HIFU) : Importance in the treatment of prostate cancer

Abstract

Radical prostatectomy and radiotherapy are the recommended standard treatment modalities for the management of prostate cancer in current clinical guidelines. With the discovery of the biological effects of piezoelectric sources on tissues, high-intensity focused ultrasound (HIFU) therapy was introduced as a new treatment modality for prostate cancer in 1980s. In early years, HIFU therapy was applied only for patients, who were not suitable for surgery due to age and comorbidities. However, with technological developments and growing clinical experiences, it is currently preferred for primary, salvage and focal therapy of prostate cancer. Although HIFU is used routinely in clinical practice in European Countries (the suggest degree 3 and the level of evidence C for localized low-grade prostate cancer in European Association of Urology guidelines), FDA approval was provided in 2015 for prostatic tissue ablation in the United States. 

In this review, we discuss the working principle, latest devices, therapeutic indications, effectiveness and results of HIFU therapy. 

Keywords

Prostate cancer , HIFU , Focal Therapy

References

• 1. Torre, L.A., et al., Global cancer statistics, 2012. CA: a cancer journal for clinicians 2015; 65: 87-108.
• 2. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA: a cancer journal for clinicians 2015;65: p. 5-29.
• 3. Gultekin, M., et al., Turkiye Kanser Istatistikleri (Cancer Statistics in Turkey). Ankara: TC Saglik Bakanligi, Türkiye Halk Sağlığı Kurumu, 2015.
• 4. Zorlu, F., et al., Prostate cancer incidence in Turkey: an epidemiological study. Asian Pac J Cancer Prev 2014; 15: p. 9125- 30.
• 5. Mottet, N., et al., EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. European urology 2017; 71: p. 618-629.
• 6. Curie, J. and P. Curie, Development by pressure of polar electricity in hemihedral crystals with inclined faces. Bull. soc. min. de France, 1880; 3: p. 90.
• 7. Biquard, P., Paul Langevin 1972.
• 8. Mahmoud, M.Z., et al., High-Intensity Focused Ultrasound (HIFU) in uterine fibroid treatment: review study. Pol J Radiol 2014; 79: p. 384-390.
• 9. Curiel, L., et al., Experimental evaluation of lesion prediction modelling in the presence of cavitation bubbles: intended for high-intensity focused ultrasound prostate treatment. Medical and Biological Engineering and Computing 2004; 42: p. 44-54.
• 10. Uchida, T., et al., Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer. The Journal of urology 2015; 193: p. 103-110.
• 11. Crouzet, S., et al., Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. European urology 2014; 65: p. 907-914.
• 12. Alkhorayef, M., et al., High-intensity focused ultrasound (HIFU) in localized prostate cancer treatment. Polish Journal of Radiology 2015; 80: p. 131.
• 13. Cordeiro, E.R., et al., High‐intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU internationa, 201;. 110:1228-1242.
• 14. Palermo, G., et al., High-intensity focused ultrasound in prostate cancer: today’s outcomes and tomorrow’s perspectives. Scandinavian journal of urology 2013; 47: p. 179-187.
• 15. CHAUSSY, C.G. and S. THÜROFF, High-intensive focused ultrasound in localized prostate cancer. Journal of endourology 2000; 14: p. 293-299.
• 16. Thüroff, S., et al., High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. Journal of Endourology 2003; 17: p. 673-677.
• 17. Poissonnier, L., et al., Control of prostate cancer by transrectal HIFU in 227 patients. European Urology 2007; 51: p. 381-387.
• 18. Mallick, S., et al., Salvage therapy using high-intensity focused ultrasound for local recurrence of prostate cancer after radiation therapy. European Urology Supplements 2006; 5: p. 132.
• 19. Gelet, A., et al., Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. Journal of Endourology 2000; 14:519-528.
• 20. Gelet, A., et al., Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004; 63: p. 625-9.
• 21. Ahmed, H., et al., High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. British journal of cancer 2009; 101: p. 19-26.
• 22. Mearini, L., et al., Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. The Journal of urology 2009; 181: 105-112.
• 23. Muto, S., et al., Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Japanese journal of clinical oncology 2008; 38:192-199.
• 24. Uchida, T., et al., Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study 2005.
• 25. Uchida, T., et al., Treatment of localized prostate cancer using high‐intensity focused ultrasound. BJU international 2006; 97:56-61.
• 26. Uchida, T., et al., Transrectal high‐intensity focused ultrasound for the treatment of localized prostate cancer: Eight‐year experience. International journal of urology 2009; 16: 881- 886.
• 27. Chaussy, C. and S. Thüroff, Results and side effects of highintensity focused ultrasound in localized prostate cancer. Journal of Endourology 2001; 15: 437-440.
• 28. Chaussy, C. and S. Thüroff, The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Current Urology Reports 2003; 4:248-252.
• 29. Gelet, A., et al., Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. European urology 2001; 40: 124-129.
• 30. Gelet, A., et al., Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004; 63:625-629.
• 31. Gelet, A., et al., PROSTATE CANCER CONTROL WITH TRANSRECTAL HIFU IN 124 PATIENTS: 7-YEARS’ACTUARIAL RESULTS. European Urology Supplements 2006; 5:133.
• 32. Blana, A., et al., Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World journal of urology 2006; 24:585-590.
• 33. Blana, A., et al., First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. european urology 2008; 53:1194-1203.
• 34. Ganzer, R., et al., Fourteen‐year oncological and functional outcomes of high‐intensity focused ultrasound in localized prostate cancer. BJU international 2013;112:322-329.
• 35. Sumitomo, M., et al., Efficacy of short-term androgen deprivation with high-intensity focused ultrasound in the treatment of prostate cancer in Japan. Urology 2008; 72:1335-1340.
• 36. Sumitomo, M., et al., Transurethral resection of the prostate immediately after high‐intensity focused ultrasound treatment for prostate cancer. International journal of urology 2010; 17: 924-930.
• 37. Shoji, S., et al., Quality of life following high‐intensity focused ultrasound for the treatment of localized prostate cancer: A prospective study. International journal of urology 2010; 17: 715-719.
• 38. Komura, K., et al., Clinically significant urethral stricture and/or subclinical urethral stricture after high-intensity focused ultrasound correlates with disease-free survival in patients with localized prostate cancer. Urologia internationalis 2011; 87:276-281.
• 39. Inoue, Y., et al., Transrectal high‐intensity focused ultrasound for treatment of localized prostate cancer. International Journal of Urology 2011; 18:358-363.
• 40. Blana, A., et al., High‐intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU international 2009; 104:1058-1062.
• 41. Hautmann, R.E., R.C. de Petriconi, and B.G. Volkmer, 25 years of experience with 1,000 neobladders: long-term complications. J Urol 2011; 185: 2207-12.
• 42. Gelet, A., et al., Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. The Journal of urology 1999; 161:156-162.
• 43. Cox, J.D., et al., Consensus statement. International Journal of Radiation Oncology Biology Physics 1997; 37:1035-1041.
• 44. Lee, H., J. Hong, and H. Choi, High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate cancer and prostatic diseases 2006; 9:439-443.
• 45. Blana, A., et al., High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004; 63: 297-300.
• 46. Walter, B., et al., Combination from TURP and high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer—experience with 70 patients. J Urologie Urogynakologie 2004; 11: 5-10.
• 47. Colombel, M., et al., Clinical results of the prostate HIFU project. European Urology Supplements 2006; 5: 491-494.
• 48. Ramsay, C.R., et al., Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health technology assessment 2015.
• 49. Chiang, P.H. and Y.Y. Liu, Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation and high-intensity focused ultrasound for localized prostate cancer. SpringerPlus 2016; 5: 1905.
• 50. Zacharakis, E., et al., The feasibility and safety of high‐intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU international 2008; 102:786-792.
• 51. Bahn, D.K., et al., Focal prostate cryoablation: initial results show cancer control and potency preservation. Journal of Endourology 2006; 20: 688-692.
• 52. Ganzer, R., et al., PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. european urology 2008; 53:547-553.
• 53. Murat, F.-J., et al., Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. European urology 2009; 55: 640- 649.
• 54. Crouzet, S., et al., Multicentric oncologic outcomes of highintensity focused ultrasound for localized prostate cancer in 803 patients. European urology 2010; 58:559-566.
• 55. Mearini, L., et al., High-intensity focused ultrasound for the treatment of prostate cancer: a prospective trial with longterm follow-up. Scandinavian journal of urology 2015; 49: 267-274.
• 56. Ripert, T., et al., Transrectal high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer: review of technical incidents and morbidity after 5 years of use. Prostate cancer and prostatic diseases 2010; 13:132-137.
• 57. Netsch, C., D. Pfeiffer, and A.J. Gross, Development of bladder outlet obstruction after a single treatment of prostate cancer with high-intensity focused ultrasound: experience with 226 patients. Journal of endourology 2010; 24:1399-1403.
• 58. Hatiboglu, G., et al., Quality of life and functional outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer. BMC urology 2017;17:5.
• 59. Crouzet, S., et al., Outcomes of HIFU for localised prostate cancer using the Ablatherm Integrate Imaging® device. Progres en urologie: journal de l’Association francaise d’urologie et de la Societe francaise d’urologie 2011; 21:191-197.
• 60. Uchida, T., et al., Five years experience of transrectal high‐intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. international Journal of Urology 2006; 13:228-233.